

# CURRICULUM VITAE

**CLIFFORD J. ROSEN, M.D.**

————— (207) 262-1176 w  
—————

## **EDUCATION:**

- 1971 University of Maine, B.S. with highest honors Biochemistry  
1975 State University of New York at Syracuse, Upstate Medical Center-M.D.

## **POSTGRADUATE TRAINING:**

- 1975-1976, Internship: Berkshire Medical Center, Pittsfield, MA; Straight Medicine  
1976-1978, Residency: Berkshire Medical Center, (University of Massachusetts Medical Center) Internal Medicine  
1978-1979, Chief residency-Internal Medicine: Berkshire Medical Center, Pittsfield, MA  
1982-1984, Endocrinology Fellowship: Dartmouth Hitchcock Medical Center, Hanover, NH.

## **ACADEMIC APPOINTMENTS:**

- 1978-1979, Instructor in Medicine, University of Massachusetts, Worcester, MA  
1982-1984, Instructor in Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH  
1986-1988, Adjunct associate professor, School of Human Development, University of Maine, Orono  
1987-1997 Chief of Medicine-St. Joseph Hospital-Bangor ME  
1988-1990, Research Assistant Professor in Human Nutrition, School of Human Development, University of Maine  
1987-1990, Committee person-3 year term:IRB, University of Maine, Orono, Maine  
1990-1993, Executive committee member USDA Study section NE-178  
1991- 1995 Research Associate Professor in Human Nutrition, School of Human Development, University of Maine  
1996- 1999 Research Professor of Nutrition and Food Sciences, University of Maine  
1991- Special Scientific Staff: Boston City Hospital, BUMC  
1992-1995 Affiliate Staff: Maine Medical Center, Portland, ME  
1992-1995 Clinical Associate Professor of Medicine: Tufts University School of Medicine, Boston MA  
1993- Special Scientific Staff: Boston University Medical Center, Boston MA  
1993- Staff Endocrinologist: University Hospital: Boston MA  
1993- Associate Clinical Professor: Boston University School of Medicine  
1993- Executive Director: Maine Center for Osteoporosis Research and Education  
1997-2005 Adjunct Staff Scientist-The Jackson Laboratory  
2000- Professor of Nutrition- University of Maine, Orono ME  
2005- Senior Staff Scientist The Jackson Laboratory

## **PROFESSIONAL SOCIETY AND STAFF POSITIONS:**

- 1979- , Internal medicine section member, Eastern Maine Medical Center and St. Joseph Hospital, Bangor, ME  
1987-1993 , Director of Endocrinology and Metabolism section, Eastern Maine Medical Center, Bangor, ME  
1984-1994 Director of Endocrinology and Metabolism St. Joseph Hospital  
1987- 1998 Chief of Medicine, St. Joseph Hospital, Bangor, Maine  
1987-1993 , Director of Diabetes Education Center, Eastern Maine Medical Center  
1986-1987, Chairman of Quality Assurance, St. Joseph Hospital,  
1988- , The Endocrine Society, member  
1989-1995, Chairman of the Research Committee, Eastern Maine Medical Center  
1989- , American Society of Bone and Mineral Research, member  
1989- , American Federation of Clinical Research, member  
1993-1995, Founding Board Member and Treasurer, Society for Clinical Densitometry  
1996-2001 Editor in Chief Journal of Clinical Densitometry  
1994- American Academy for the Advancement of Science, member  
1995- New York Academy of Sciences, member  
1996- Endocrinologist, Veterans Administration Hospital, Togus ME

**STATE CERTIFICATIONS:**

1. National Board of Medical Examiners - 1976
2. American Board of Internal Medicine - 1978
3. American Board of Internal Medicine - Subspecialty Endocrinology & Metabolism-1985

**MEDICAL LICENSURE:**

- 1979- STATE OF MAINE, REGISTRATION \_\_\_\_\_  
1975-79;1993-2000 STATE OF MASSACHUSETTS  
2001- Province of New Brunswick: Border License

**PROFESSIONAL POSITIONS – AWARDS:**

1. Teacher of the Year - Family Practice Residency, Eastern Maine Medical Center; 1987.
2. Course Director and Affiliate - Advanced Life Support; 1986-90
3. Faculty - School of Nurse Anesthesia, Eastern Maine Medical Center
4. Member - Physicians for Social Responsibility; 1979-1987.
5. Sponsor - Summer Research Fellowship, The Endocrine Society; 1989,1995
6. Member - American Society of Bone & Mineral Research; 1989.
7. Member - American Federation for Clinical Research; 1989.
8. Member of the Scientific Advisory Council: Institute for Cellular Research- Bangor Maine,
9. \_\_\_\_\_
10. Fellowship sponsor-Visiting research associate: ECFMG Dr. \_\_\_\_\_, Peoples Republic of China; 1992-1994
11. \_\_\_\_\_
12. \_\_\_\_\_
13. Founder-Maine Physicians for a National Health Plan; 1991
14. National Health Policy Advisory Council; 1993
15. National Faculty Member: Core Content Review of Family Medicine; 1993
16. NASA Certificate of appreciation – Space Physiology and Countermeasure Peer Review Panel; 1993
17. The Katherine Musgrave Maine Nutrition Council Public Service Award; March 1994
18. Steering Committee: Society for Clinical Densitometry; 1993
19. Boy Frame Clinical Awards Committee (ASBMR);1993-1996
20. International Expert Panel: Detection and Interpretation of Bone Mass; 1994
21. Visiting Professor in Endocrinology-Boots Pharmaceuticals; 1994
22. Who's Who in Science and Engineering; 1995
23. Program Chairman: First/Third Annual Meeting: Society of Clinical Densitometry; 1994, 1997
24. Public Affairs Committee-American Society of Bone Mineral Research; 1994-1998
25. Co-chair: Skeletal Models of Aging Workshop: ASBMR; 1995,1996,1997
26. Visiting Nutrition Professorship: National Dairy Council; 1996
27. Scientific Advisory Board: National Osteoporosis Foundation; 1995-99
28. Endocrine Society: Mentor-Summer Student Fellowship; 1995
29. Scientific Advisory Board: Biologic Effects of Light- Atlanta October; 1995
30. Member, Data Safety Monitoring Board: NIH; 1995-1998
31. \_\_\_\_\_
32. Chairperson: Evidence Based Review of Osteoporosis; 1996-2000
33. Education Committee-National Osteoporosis Foundation; 1995-98
34. Glenn Foundation Endocrinology and Aging Research Award; 1996
35. Best Doctors in America: Northeast Region;1996-1997
36. \_\_\_\_\_
37. Scientific Advisory Board: Peripheral Bone Measurements, Norland Scientific
38. Who's Who in Medicine and Health Care; 1998-2000
39. Research Advisory Council-The Osteoporosis Business Coalition; 1998
40. 2000 Outstanding Scientists of the 20<sup>th</sup> century
41. Career Alumni Award- University of Maine; 2001
42. Distinguished Service to Medicine Award, Maine Medical Association; 2000

43. \_\_\_\_\_
44. President -American Society of Bone and Mineral Research (ASBMR); 2002-2003
45. Great Teachers in Clinical Medicine Lecture Series: NIH; December 2002
46. Member NIH Review Panel: Oral Biology and Medicine; 1998-2002;
47. Permanent Chair: NIH Review Panel: OBM-2; SBDD NIH Review Panel; 2002-2004
48. Associate Editor- J Bone Mineral Research 2003- 2008
49. Best Doctors of America- 2004

#### **PROGRAM COMMITTEES:**

- 1) Chairperson-First Annual Society of Clinical Densitometry, Chantilly, VA; 1994
- 2) Co-Chair: New England Bone Club; 1995-1998;
- 3) Committee Chairperson: NOF- 4th International Meeting-Washington DC; 1997
- 4) Co-Chair: Third Annual Society of Clinical Densitometry-San Diego CA; 1997
- 5) Program Tri-Chair: Skeletal Aging: Am Soc Bone Min Res; 1995-1998
- 6) Program Chair: Boy Frame Working Group Am Soc Bone Min Res; 1996
- 7) Program Co-Chair: The NIH Conference on Growth Hormone-IGF Axis in Aging; 1997
- 8) Program Committee: American Society for Bone and Mineral Research; 1997, 1998
- 9) Program Committee; Third International Osteoporosis Program-Beijing China; 1999
- 10) Chair-Atlantic Endocrine Society-Bar Harbor ME; 1999
- 11) Chair: Advocacy Committee: ASBMR; 1999-2002
- 12) Chair DSMB-NIH Combination Therapy Alendronate and low dose estrogen
- 13) Chair-Data Oversight- Uniform Data Bases for Bone Densitometry
- 14) DSMB Chair NIH-NIA trial Calcium therapy in osteoporosis; combination therapy for osteoporosis
- 15) Endocrine Society: Meetings and Education Committee person; 2002-2005
- 16) Program Committee: Growth Hormone and IGF Symposium; 2002
- 17) Gordon Conference: IGFs: Ventura California; 2003
- 18) U.S. FDA- Endocrine and Metabolic Regulatory Panel 2003
- 19) Maine Governor's Panel on Health Care Reform 2003- Legislative Confirmation with Governor Nomination

#### **PUBLICATIONS IN PEER-REVIEWED JOURNALS (From more than 170 original research papers):**

- 1.) **Rosen CJ**, Douglas, G. and Buck, L. Liver Abscess Due to Hemophilus Parainfluenzae. Journal of Clinical Microbiology, 1979 9:229-233.
- 2.) **Rosen CJ**, Hassler G. Metastatic Pituitary Disease: Case Report and Review of the Literature. Maine Medical Journal. 1980;71: 238-242.
- 3.) Musgrave KO, Leclerc H, **Rosen CJ**, Cook RA, and Giambalvo L. Validation of a Quantitative Food Frequency Questionnaire for Calcium Consumption. Journal of the American Dietetic Association.1989; 89: 1484-1488.
- 4.) Davee AM, **Rosen CJ**, Adler RA. Exercise Patterns and Trabecular Bone Density in College Women. J Bone Min Res 1990;5:245-250.
- 5.) **Rosen CJ**, Usiskin K, Owens MA, et al. T-Lymphocyte Surface Antigen Markers in Osteoporosis. J Bone Min Res 1990;5:851-855.
- 6.) Donahue LR, Hunter SJ, Sherblom AP, **Rosen CJ**. Age-related changes in Serum Insulin-Like Growth Factor Binding Proteins in Women. J Clin Endocrinol Metab 1990; 71:575-579.

- 7.) Hunter SJ, **Rosen CJ**, and Gay CV. In Vitro resorptive activity of isolated chick osteoclasts: Effect of carbonic anhydrase inhibition" J Bone Min Res 1991, 6:61-66.
- 8.) LaTour D, Linkhart T, Baylink DJ, Mohan S, **Rosen C**, Strong DD. PTH stimulates the elaboration of inhibitory insulin-like growth factor binding protein. in Osteoporosis,1990. Ed by C.Christiansen. p259-263.Copenhagen,Denmark.
- 9.) **Rosen C**, Donahue LR, Hunter S, Holick M, Kavookjian H, Kirshenbaum A, Mohan S and Baylink DJ. The 24/25kD serum insulin-like growth factor binding protein is increased in elderly women with fractures. J Clin Endocrinol Metab. 1992;74:24-28.
- 10.)**Rosen CJ**, Hartz E, Mroz F Segal H. Primary hyperparathyroidism in a patient with multiple myeloma: apparent cure after fine needle aspiration. J Am Ger Soc. 1992;40:703-705.
- 11.)**Rosen C** and Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after restoration of euthyroidism. J Clin Endocrinol Metab. 1992;75:1531-1534
- 12.)Bing-You RG, Denis MC and **Rosen CJ**. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlation with growth hormone, responses to GHRH, IGF-I and IGFBP-3.Calcified Tissue International, 1993: 52: 183-187.
- 13.)Hobbs CJ, Plymate SR, **Rosen C**, Adler RA. Testosterone Administration Increases Insulin-like Growth Factor-I Levels in Normal Men. J Clin Endocrinol Metab.1993;77:776-780.
- 14.)Scharla SH, Strong DD, **Rosen CJ** et al. 1,25 Dihydroxyvitamin D increases expression of IGFBP-4 in human osteoblast like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab.1993;77:1190-1197.
- 15.)**Rosen CJ**, Holick MJ, Chen T, Hunter SJ, Morrison AM, Storm D, Musgrave KO, and Zhou H. Seasonal Effect of Sunlight on Bone Mass in Elderly Women.in The Biologic Effects of Light.1993eds by EJ Jung, M Holick. DeGruyter Pub.Berlin and New York. 1994 pp 16-27.
- 16.)**Rosen CJ**, Morrison A, Zhou,H, Storm D, Hunter SJ, Musgrave KO, Chen T, Wen-Wei, Holick MF. The Effects of Sunlight and diet on bone loss in elderly women from rural Maine. Maine Journal of Health Issues. 1994;1:3 1-8.
- 17.)**Rosen CJ** and Adler RA. Glucorticoids and Bone Mass. Clinics in Endocrinology and Metabolism.1994;23: 641-654
- 18.)**Rosen CJ**, Donahue LR and Hunter SJ. Insulin-like growth factors and Bone: The osteoporosis connection. Proceedings of the Society for Experimental Biology and Medicine.1994;206:83-102.
- 19.)**Rosen CJ**, Morrison T, Hunter SJ, Holick MF, Chen T, Zhou H, Wen-Wei and Storm D. Elderly Women in Northern New England Exhibit Seasonal Changes in Bone Mass and Calcitropic Hormones. Bone and Mineral 1994;25:83-92.
- 20.)Poehlman ET, **Rosen CJ**, and Copeland KC. The Influence of endurance training on IGF-I in older individuals. Metabolism,1994.43:1401-1405.

- 21.) **Rosen CJ**, Holick MF, Millard PF. Premature Graying of Hair is a Risk Marker for Osteopenia. *J Clin Endocrinol Metab* 1994;79:854-858.
- 22.) Shewmon DA, Stock JL, **Rosen CJ**, Heiniluoma KM, Hogue MM, Morrison AM, Doyle EM, Ukena T, Weale G, Baker S. The effects of estrogen and tamoxifen on lipoprotein (a) and IGF-I in healthy postmenopausal women: a randomized, placebo-controlled trial. *Arteriosclerosis and Thrombosis* 1994;14:1586-1593.
- 23.) Nadeau DA, Nair KS, **Rosen C**, Copeland KC. Effect of Octreotide on GH-induced IGF-I production in Humans. *Endocrinology and Metabolism*.1994;.1: 181-185.
- 24.) Rosen HN, Tollin S, Balena R, Middlebrooks BA, Beamer WG, Donahue LR, **Rosen CJ**, Turner A, Holick M and Greenspan SL. Differentiating between orchietomized Rats and controls using measurements of trabecular bone density. *Calcif Tiss Int* 1995;57:35-39.
- 25.) Plymate SR, Birnbaum RS and **Rosen CJ** Proteolysis of IGFBP-3 in the male reproductive tract. *J Clin Endocrinol Metab*.1996; 81:618-624.
- 26.) Miller PD, **Rosen C** and Bonnick S. Guidelines for the Clinical Utilization of Bone Mass Measurements in the Adult Population. *Calcif Tiss Int* 1995;57:251-252.
- 27.) Beamer WG, Donahue LR, **Rosen CJ** and Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. *BONE* 1996;18;5:397-405.
- 28.) Rall LC, **Rosen CJ**, Dolnikowski G, Hartman WJ, Lundgren N, Abad LW, Dinarello CA and Roubenoff R. Protein Metabolism in RA and aging: Effects of Strength Training, Methotrexate and TNF-alpha. *Arthritis and Rheumatism* 1996;39:1115-1124.
- 29.) **Rosen CJ** and Kessenich CR. Mechanisms of seasonal bone loss in elderly women. in Biologic Effects of Sunlight. Ed by MF Holick and EJ Jung. de Gruyter 1996 pp56-64
- 30.) Grogean T, Vereault D, Millard PS, Kiel D, MacLEAn D, Orwoll E, Greenspan S and **Rosen CJ**. A Comparative Analysis of Methods to Measure IGF-I in Human Serum. *Endocrine and Metab* 1997;4:109-114.
- 31.) Prior RL, Crim MC, Sataneda C, Lammi-Keefe C, Dawson-Hughes B, **Rosen CJ** and Spindler AA. Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. *JACN* 1996;15(3):237-247.
- 32.) Goldring MB, Lederer LJ, Suen LF, Vereault D, **Rosen CJ**. Differential expression of IGFbps by immortalized human chondrocytes. Orthoped Transactions, in *J Bone J Surg* 1996.
- 33.) Smith EL, Cress ME, Checovich MM and **Rosen CJ**. Effect of physical training on Bone Mineral Density in Septuagenarian Women. *Calcif Tiss Int*;1998
- 34.) Miller PD, Bonnick SM and **Rosen CJ**. Consensus of an International Conference on the Clinical Utilization of Bone Mineral Density Measurements. *Calcif Tiss Int* 1996;58:207-214.
- 35.) Chestnut C, Notelovitz M, Clark G, Drinkwater B, **Rosen C**, Bell N, English S, Johnston CC, Cain D, Flessland

K, Mallinak N. Use of the N-telopeptide of type I collagen to monitor the effect of therapy and predict changes in bone mineral density in postmenopausal women treated with hormone replacement therapy. *Am J Med*;1997;102:29-37.

- 36.) **Rosen CJ** and Glowacki J. Age, hormone and cytokine dependence of the skeletal IGF-regulatory system in human marrow. *Orthopedic Transactions in JI Bone Joint Surg* 1995; 1085.
- 37.) Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, **Rosen CJ** et al. Development and validation of the mini-osteoporosis quality of life questionnaire in osteoporotic women with back pain due to vertebral fractures. *Osteoporosis Quality of Life Study Group: Osteoporosis International*. 1999;10: 207-213.
- 38.) Rogers J, Mahaney MC, Beamer WG, Donahue LR and **Rosen CJ**. Beyond one gene-one disease: alternative strategies of deciphering genetic determinants of osteoporosis. *Calcif Tiss Int* 1997;60:225-228.
- 39.) Poehlman ET, Toth MJ, Ades PA and **Rosen CJ**. Menopause associated changes in plasma lipids insulin-like growth factor-I and blood pressure: a longitudinal study. *Eur J Clin Invest*. 1997;27:322-326.
- 40.) Miller PD, Bonnick SI and **Rosen CJ**. Clinical Utility of Bone Mass Measurements in Adults: Consensus of an International Panel. *Seminars in Arth Rheum* 1996;25:361-372.
- 41.) Poehlman ET, Toth MA, Goran MI, Carpenter W, Newhouse P and **Rosen CJ**. Daily energy expenditure in free-living non-institutionalized Alzheimer's Patients. *Neurology*, 1997;997-1002.
- 42.) Kurland E. **Rosen CJ**, Cosman F, McMahon D, Shane E, Lindsay R, Dempster D and Bilezikian. Osteoporosis in men: abnormalities in the IGF-I axis. *J Clin Endocrinol Metab* 1997; 82:2799-2805
- 43.) Linkhart TA, Linkhart SG, Farley JR, Dimai HP, Beamer WG, Donahue LR, **Rosen CJ** and Baylink DJ. Osteoclast formation in bone marrow cultures from two inbred strains of mice with different bone densities. *J Bone Min Research* 1999;13;1: 35-42.
- 44.) **Rosen CJ**, Chesnut CH and Mallinak NJS. The Predictive value of biochemical markers of bone turnover in early postmenopausal women treated with hormone replacement or calcium supplementation. *J Clin Endocrinol Metab* 1997;82:1904-1910
- 45.) **Rosen CJ**, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart T, Linkhart S Mohan S and Baylink DJ. Circulating and skeletal IGF-I concentrations in Two inbred strains of mice with different bone densities. *BONE* 1997 21;3:217-223
- 46.) Kiel DP, Puhl J, **Rosen CJ**, Berg K, Murphy JB and MacLean DB. Association of IGF-I with body composition, muscle strength, physical performance and self-reported mobility among older persons with functional limitations. *J Am Ger Soc*, 1998 46:822-828.
- 47.) **Rosen CJ**, Donahue LR, Beamer WG, Adler RA, Kurland ES and Bilezikian JP. IGF-I and osteoporosis: lessons from mice and men. in Nutritional Symposium on Osteoporosis. Springer-Verlag, Berlin 1998 .
- 48.) **Rosen CJ**, Glowacki J and Craig W. Sex steroids, aging and IGF regulatory system: implications for the management of older postmenopausal women. *Journal of Nutrition Health and Aging*;1998;2:333-339.

- 49.) **Rosen CJ**, Vereault D, Steffens C and Glowacki J. Effects of age and estrogen status on the IGF regulatory system: studies in human marrow cells. *Endocrine* 1997 ;7:77-80.
- 50.) Davine A, **Rosen CJ**, Baylink DJ and Prince RL. Effects of zinc and other nutritional factors on IGF-I and IGF binding proteins in postmenopausal women. *Am J Clin Nutrition* 1998;68:200-206.
- 51.) Kessenich CR, Guyatt GH and **Rosen CJ**. Health Related Quality of Life and Participation in Osteoporosis Clinical Trials. *Calcif Tiss Int.* 1998 62:3;189-191.
- 52.) Roubenoff R, Rall LC, Veldhuis JD, Kehayias JJ, **Rosen C**, Nicolson M, Lundgren N and Reichlin S. The Relationship between GH kinetics and sarcopenia in postmenopausal women: The role of fat mass and leptin. *J Clin Endocr Metab* 1998;83:1502-1506.
- 53.) Klein GL, Wolf SE, Langman CB, **Rosen CJ**, Mohan S, Keenan BS, Matin S, Steffen C, Nicolai M, Sailer DE and Herndon D. Rising serum levels of IGF inhibitory binding protein may contribute to short-term failure of rhGH to stimulate bone formation in children following severe bone injury. *J Clin Endocrinol Metab* 1998;83:21-24.
- 54.) Dimai HP, Linkhart TA, Linkhart SG, Donahue LR, Beamer WG, **Rosen CJ**, Farley JR, and Baylink DJ. Alkaline Phosphatase Levels and osteoprogenitor cell numbers suggest that bone formation may contribute to peak bone density differences between two inbred strains of mice. *Bone* 1998;22;211-216.
- 55.) **Rosen CJ** Vereault DA, Raymond JP, Hoffman RA, Craig WY. IGF-I: A risk factor for restenosis after coronary artery angioplasty. *Circulation* 1997;96: 8: 502.
- 56.) Kurland ES, Chan FKW, **Rosen CJ**, and Bilezikian JP. Growth hormone axis in men with idiopathic osteoporosis. *J Clin Endocrinol Metab* 1998;83;2576-2579.
- 57.) **Rosen CJ**, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J and Bilezikian JP. An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of bone mineral density. *J Clin Endocrinol Metab* 1998;83:2286-2290.
- 58.) Donahue LR and **Rosen CJ**. IGFs and Bone: The osteoporosis connection revisited. *Proceedings of the Society for Experimental Biology and Medicine* 1998;219;1-7
- 59.) Shalet SM, Rosenfeld RG and the Faculty. Growth Hormone replacement therapy during the transition of patients with childhood onset GHD into adulthood: what are the issues? 24th International Symposium on GH and Growth Factors in Endocrinology and Metabolism. Ed by Bouillon R, Baumann GP et al Growth Hormone and IGF Research 8:177-184.
- 60.) Xu X, Nui T, Kuo A and **Rosen CJ**. Forearm bone mineral density in mainland Chinese women: implications for genetic screening. *J Clin Densitometry* 1998;2:34-38.
- 61.) Osteoporosis Quality of Life Study Group. Development and Validation of the Mini-Osteoporosis Quality of Life Questionnaire in Osteoporotic Women with Back Pain due to Vertebral Fractures. *Osteoporosis Int* 1999
- 62.) Storm D, Smith-Porter E, Musgrave KO, Vereault D, Patton C, Kessenich CR, Eslin R, Mohan S, Chen T, Holick MF and **Rosen CJ**. Calcium supplementation prevents Seasonal bone loss and changes in biochemical

markers of bone turnover in elderly New England women: A Randomized Placebo-Controlled Trial. *J Clin Endocrinol Metab* 83;3817-3826

- 63.) Rackoff PJ and **Rosen CJ**. Peripheral Bone Mass Measurements: Current and Future Perspectives on Quantitative Ultrasound and Peripheral DXA. *J Clin Densitometry* 1998;1;287-294
- 64.) **Rosen CJ** and Kiel DP. Age-related osteoporosis. in *The Primer on Metabolic Bone Diseases* 1998; Lippincott Raven; 4:57-59.
- 65.) Patton CL, Millard PS, Kessenich CR, Storm D, Kinnicut E and **Rosen CJ**. Screening heel ultrasound and risk factors for osteoporosis among lesbians and heterosexual women. *J of Women's Health*. 1998; 7:909-915.
- 66.) Langlois JA, **Rosen CJ**, Visser M, Hannan M, Harris T, Wilson PFW, Kiel D. The association between IGF-I and bone mineral density in women and men: the Framingham heart study. *J Clin Endocrinol Metab* 1998 83;4257-4262.
- 67.) Beamer WG, Shultz K, Churchill G, Frankel W, Basylink Dj, **Rosen CJ** and Donahue LR. Identification of Quantitative Trait Loci for Bone Density in C57Bl/6J and CAST/EiJ Inbred Mice. *Mammalian Genome* 1999; 10: 1043-1049.
- 68.) **Rosen CJ**. Cervical Osteoporosis. *J Clin Densitometry* 1999; 2:55-58.
- 69.) Heaney RP, McCarron DA, Dawson-Hughes B, Oparil S, Berga SL, Stern JS, Barr SI and **Rosen CJ**. Dietary Changes Favorably Affect Bone Remodeling. *J Am Diet Assoc* 1999;99:1228-1233 .
- 70.) Niu T, Chen C, Ni J, Wang B, Fang Z, Cummings SR, and **Rosen CJ** and Xiping Xu. Familial Aggregation of Forearm Bone Mineral Density in Chinese. *Epidemiology* 2001.
- 71.) **Rosen CJ**, Kiel DP, Langlois JA, Visser M. Association between IGF-I and BMD: Further Evidence Linking IGF-I to Breast Cancer Risk. *J Clin Endocrinol Metab* 1999 84; 1761.
- 72.) Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL and **Rosen CJ**. Enhancement of bone mass in osteoporotic women with PTH followed by alendronate. *J Clin Endocrinol Metab* 2000;85:2129-2134
- 73.) Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Diewati A, Santana J, **Rosen CJ** and Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65.. *J Clin Endo Metab* 1999;84:2647-2653.
- 74.) Sites C, Poehlman E, Tishler M, **Rosen CJ**. Effect of short term medroxyprogesterone on left ventricular mass: role of IGF-I. *METABOLISM* 1999 ;1328-1331.
- 75.) Kodama Y, Dimai HP, Wergedal J, Sheng M, Malpe R, Kutilek S, Beamer W, Donahue LR, **Rosen CJ**, Baylink DJ and Farley J. Cortical Tibial Bone Volume in two strains of mice: a study of the effect of sciatic neurectomy and the genetic regulation of bone response to mechanical loading. *Bone* 1999;25:183-190.
- 76.) Matkovic V, Badenhop NE, Landoll JD, Ilic JZ, **Rosen CJ** and Buell JL. Skeletal growth in a nutrition perspective: genetic and endocrine interaction. In *Prevention of Osteoporosis-a Pediatric Task in Pediatric*



Osteology ed by Matkovic and Schonau L 1998 p53-78. Academic Press San Diego CA.

- 77.) Niu T, Chen C, Cordell H, Yang J, Wang B, Wang, Z, Fang Z, Schork NJ, **Rosen CJ** and Xu X. A genome wide scan for loci linked to forearm bone mineral density. *Hum Genet* 1999; 104(3) 226-233.
- 78.) Hadan ST, Glowacki J, Hurwitz S, **Rosen C**, LeBoff. Effects of age on serum DHEA, IGF-I and IL-6 in women. *Calcified Tissue International*;2000;;66: 414-418
- 79.) Crawford CG, Beamer WG, **Rosen CJ**, Baylink DJ, Richman C, Barker J. Characterization of and mapping of the mouse mutation spontaneous fracture: a model for osteoporosis. *Bone* 2000 :5:619-627.
- 80.) Goodman-Gruen D, Barrett-Connor E, **Rosen CJ**. IGF-I and ischemic heart disease. *J Am Geriatric Soc* 2000; 48:860-861.
- 81.) Wallach S, Cohen S, Reid D, Hughes RA, Hosking DJ, Laan RF, Doherty SA, Maricic M, **Rosen C**, Brown J, Barton I and Chines AA. Effects of risedronate on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 2000;67:277-285
- 82.) Toth M **Rosen CJ**, Poehlman EC. Body composition and metabolic indices in postmenopausal women. *J Clin Endocrinol Metab* 2000 ;85:1382-1387.
- 83.) Robinson TL, Snow C, **Rosen CJ**. Exercise patterns and body composition in female athletes. *Med Sports Sci* 2000: 32:1902-1907.
- 84.) Zhao G, Faugere MCM, Langub MC, Geng Z, Wang J, Nakayama T, Pike JW, Chernaused SD, **Rosen CJ**, Malluche H, Fagin JA and Clemens TL. Targeted Overexpression of IGF-I to Osteoblasts of Transgenic Mice Increases Trabecular Bone Volume. *Endocrinology* 2000:2674-2682.
- 85.) Kodama Y, Umemura Y, Nagasawa S, Beamer WG, Donahue LR, **Rosen C**, Baylink DJ and Farley JR. Exercise and Mechanical Loading Increase Periosteal Bone Formation and Whole Bone Strength in C57Bl/6J mice but not in C3H/HeJ Mice. *Calcif Tiss Int* 2000 ;66:298-306.
- 86.) **Rosen CJ**, Donahue LR, Schultz K, Churchill G, Burgess JK, Powell DR and Beamer WG. Mapping quantitative trait loci (QTLs) for serum IGF-I in mice. *Bone* 2000;27:521-528.
- 87.) Sheng MH, Baylink DJ, Beamer WG, Donahue LR, **Rosen CJ**, Lau KH, Wedgedal JE. Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ high density, than C57Bl/6J (low density) mice during growth. *Bone* 1999;25:421-429.
- 88.) Turner CH, Hsieh YF, Muller R, Bouxsein ML, **Rosen CJ**, McCrann ME, Donahue LR and Beamer WG. Variation in bone biomechanical properties and microstructure in BXH Recombinant inbred mice. *J Bone Min Res* 2001;16:206-214
- 89.) Kodama Y, Miyakoshi N, Linkhart TL, Wedgedal J, Srivastava A, Beamer W, Donahue LR, **Rosen CJ**, Baylink DJ, Farely J. Effects of Dietary calcium Depletion and Repletion on Dynamic Determinants of Tibial Bone Volume in Two Inbred Strains of Mice. *Bone* 2000;2000;27:445-452.
- 90.) Turner CH, Hsieh Y, Muller R, Bouxsein ML, Baylink DJ, **Rosen CJ**, Grynpas MD, Donahue LR and Beamer

WG. Genetic Regulation of Cortical and Trabecular Bone Strength and Microstructure in Inbred Strains of Mice. *J Bone Min Res* 2000;15:1126-1131.

- 91.) Kessenich CR, Guyatt GH, Patton CL, Griffith LE, Hamlin A, and **Rosen CJ**. Support Group Intervention for Women With Osteoporosis. *Rehabilitation Nursing* 2000;25:88-92.
- 92.) Kodama Y, Miyakoshi N, Linkhart TA, Wergedal J, Srivastava A, Beamer W, Donahue LR, **Rosen C**, Baylink DJ and Farley J. Effects of dietary calcium depletion and repletion on dynamic determinants of tibial bone volume in two inbred strains of mice. *Bone* 2000;27:445-452.
- 93.) **Rosen CJ**, Churchill GA, Donahue LR, Shultz KL, Burgess JK, Ackert C, Powell DR and Beamer WG. Mapping QTLs for serum IGF-I levels in mice. *Bone* 27: 521-528; 2000.
- 94.) Kurland ES, Cosman F, McMahon D, **Rosen CJ**, Lindsay R and Bilezikian JP. PTH as a therapy for idiopathic osteoporosis in men: effects on BMD and Bone markers. *J Clin Endocrinol Metab* 2000; 85: 3069-3076.
- 95.) Richman C, Kutilek S, Miyakoshi N, Srivastava AK, Beamer WG, Donahue LR, **Rosen CJ**, Wergedal JE, Baylink DJ and Mohan S. Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H and B6 mice. *J Bone Min Res* 2001; 16: 386-398.
- 96.) Beamer WG, Shultz KL, Donahue LR, Churchill GA, Sen S, Wergedal JR, Baylink DJ and **Rosen CJ**. Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ Inbred Strains of Mice. *J Bone Min Res* 2001 16:1195-1206.
- 97.) Cranney A, Guyatt A, Krolicki N, Welch V, ORAG et al (**Cliff Rosen Chair**) A Meta-Analysis of Etidronate for the treatment of osteoporosis. *Osteoporosis International* 2001; 12: 140-151.
- 98.) Hennessey JV, Chromiak JA, Ventura SD, Reinert SE, Puhl J, Kiel DP, **Rosen CJ**, Vandenberg H, Maclean DB. Growth hormone administration and/or exercise effects on muscle fiber type and diameter in the moderately frail elderly. *J Am Ger Soc* 2001: 49: 852-858
- 99.) Milne M, Quali JM, **Rosen CJ** and Baran DT. IGF binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. *J Cell Biochem* 2001 81: 229-240.
- 100.) Bikle D, Majumdar S, Laib A, Powell-Braxton L, **Rosen CJ**, Beamer W, Nauman E, Leary C and Halloran B. The Skeletal Structure of IGF-I Deficient Mice. *J Bone Min Res* 2001, 16:2320-2330.
- 101.) Drake WM, McClung M, Njeh CF, Genant HK, **Rosen CJ**, Watts N and Kendler DL. Multisite Bone Ultrasound measurement on North American Female Reference Population.. *J Clin Densitometry* 2001; 4; 3: 239-249.
- 102.) Bouxsein ML, **Rosen CJ** Turner CH, Ackert CL, Shultz KL, Donahue LR, Churchill G, Adamo ML, Powell DR, Turner RT, Muller R, Beamer WG. Generation of a new congenic mouse strain to test the relationship among serum IGF-I, bone mineral density and skeletal morphology in vivo. *J Bone Min Res* 2002 ;17: 570-579.
- 103.) Gordon CM, Goodman E, Emans J, Grace E, Kecker KA, **Rosen CJ**, Gundberg CM, LeBoff MS.

Physiologic regulators of bone turnover in young women with anorexia nervosa. *Journal of Pediatrics*. 2002 141(1):64-70

- 104.) Boonen S, **Rosen CJ**, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vandershueren D and Geusens P. Musculoskeletal Effects of the rhIGF-I/IGFBP-3 complex in osteoporotic Patients with proximal femoral fracture. *J Clin Endocrinol Metab* 2002 ;87:1593-1599.
- 105.) Guyatt G, Cranney A, Griffith L, Walter S, Krolicki N, Favus, M and **Rosen C**. Summary of Meta-analyses of Therapies for Postmenopausal Osteoporosis and the Relationship between Bone Density and Fractures. *Endocrine and Metabolism Clinics of North America* 2002 31(3):659-79, xii.
- 106.) Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, **Rosen CJ**, Beamer W, Majumdar S, Halloran BP IGF-I is required for the anabolic actions of PTH on mouse bone. *J Bone Min Res* 2002 17:1570-1580
- 107.) Robert E. Schoen MD, MPH, Jeff Schragin MD, Joel L. Weissfeld MD, MPH, F. Leland Thaete MD, Rhobert W. Evans PhD, **Clifford J. Rosen MD**, Lewis H. Kuller MD, DrPH. Lack Of Association Between Adipose Tissue Distribution And IGF-I And IGFBP-3 In Men And Women *Cancer Epidemiol Biomarkers Prev* 11(6):581-6.
- 108.) Sakata T, Halloran BP, Elalieh HZ, Munson SJ, Rudner L, Venton L, Ginzinger D, **Rosen CJ**, and Bikle DD. 2003 Skeletal Unloading induces resistance to IGF-I on bone formation. *Bone* 32 (6): 669-80.
- 109.) Turner, CH Sun Q, Schriefer J, Pitner J, Price J, Bouxsein ML, **Rosen CJ**, Donahue LR, Shultz KL, Beamer WG (2002) Congenic mouse strains reveal gender-specific genetic regulation of bone structure. *Transactions of the Orthopaedic Research Society* 27, 42.
- 110.) Pratipanawatr T, Pratipanawatr W, **Rosen CJ**, Berria R, Bajaj M, Cusi K, Mandarino L, Kashayap S, Belfort R, and Defronzo R. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects 2002. *AJ Physiol Endocrinol Metab* 282; Jun;282(6):E1360-8.
- 111.) Rubin J, Ackert-Bicknell, CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG and **Rosen CJ**. IGF-I acts as a coupling factor for bone remodeling, regulating OPG and RANKL in vitro and OPG in vivo. *J Clin Endocrinol Metab* 2002;87:4273-4279
- 112.) Yakar S, **Rosen C**, Beamer WG, Ackert C, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk, Boisclair YR and LeRoith D. Circulating levels of IGF-I directly regulate bone growth and density. *J Clin Invest* 2002;110:771-781.
- 113.) Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, **Rosen CJ**, Gundberg CM, LeBoff MS. Effect of oral DHEA on bone density in young women with anorexia nervosa: a randomized trial. *J Clin Endocrinol Metab* 2002:4935-4942
- 114.) Shultz KL, Donahue LR, Bouxsein ML, Baylink DJ, **Rosen CJ** and Beamer WG. Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral BMD. *J Bone Min Res* 2003; 18:175-185
- 115.) Zhang M, Xuan S, Bouxsein ML, Stechow D, Akeno N, Faugere M, Maulluche H, Zhao G, **Rosen CJ**, Efstriadiadis A, and Clemens TL. Osteoblast specific Knockout of the IGF receptor gene reveals an essential role of IGF signaling in Bone Matrix Mineralization. *J Biol Chem* 2002 46:44005-44012
- 116.) Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, **Rosen C** the Osteoporosis Methodology Group and the Osteoporosis Advisory Group. Summary of Meta Analyses of Therapies for Postmenopausal Osteoporosis. 2002; *Endocrine Reviews* 23: 570-579.

- 117.) Karasik D, **Rosen CJ**, Hannan MT, Broe KE, Dawson Hughes, B, Gangon DR, Wilson PWF, Visser M, Langlois JA, Mohan S and Kiel DP. IGFBP-4, -5 and BMD in Elderly men and Women. *Calcified Tissue International* 2002;71:323-328.
- 118.) Solomon DH, Connelly MT, **Rosen CJ**, Dawson-Hughes B, Kiel DP, Greenspan SL, Leib ES, Holick M, Miguel A and Finklestein JS. 2003 Factors related to the use of bone densitometry survey responses of 494 physicians in New England. *Osteoporosis Int* 14 (2): 124-9.
- 119.) **Rosen CJ** and Brown S. Prolonged Hypocalcemia after Intravenous Bisphosphonate use in Occult Osteomalacia. *NE J Med* 2003;348:1503-1504.
- 120.) Rubin J, Chung LWK, Fan X, Zhu L, Murphy TC, Nanes MS and **Rosen CJ**. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. *Prostate* 2004;58:41-49
- 121.) Gordon CM, Goodman E, Emans SJ, Grace E, Becker KA, **Rosen CJ**, Gundberg CM, LeBoff MS. Physiologic regulators of bone turnover in young women with anorexia nervosa. *J Pediatr.* 2002 Jul;141(1):64-70.
- 122.) Gu W, Li X, Lau KH, Edderkaoui B, Donahae LR, **Rosen CJ**, Beamer WG, Shultz KL, Srivastava A, Mohan S, Baylink DJ. Gene expression between a congenic strain that contains a quantitative trait locus of high bone density from CAST/EiJ and its wild-type strain C57BL/6J. *Funct Integr Genomics.* 2002 Apr;1(6):375-86.
- 123.) Li, Yulin, Iida K, O'Neil JO, Zhang P, Li S, Frank A, Gabai A, Zambito F, Liang SH, **Rosen CJ**, and Cavener DR. 2003 PERK eIF2 a kinase regulates neonatal growth by controlling the expression of circulating IGF-I derived from the liver. *Endocrinology* 144 (8): 3505-13.
- 124.) Zhang M, Faugere MC, Maulluche H, **Rosen CJ**, Chernausk SD and Clemens TL. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. *J Bone Min Res* 2003: 836-844.
- 125.) Sullivan SS, Cobb JL, **Rosen CJ**, Holick MF, Chen TC, Kimlin MG, Parisi AV. Assessment of sun exposure in adolescent girls using activity diaries. *Nutrition Research.* 2003;23(5):631-644.
- 126.) Tuckerman K, Hofmaster P, **Rosen CJ**, Turi M. Bone density in ambulatory and immobile children *J Clin Densitom.* 2002;5(4):327-34.
- 127.) Silha J, Mishra S, **Rosen CJ**, Beamer WG, Turner RT, Powell DL, Murphy JL. Perturbations in Bone Formation and Resorption in Insulin-Like Growth Factor Binding Protein-3 Transgenic Mice. *J Bone Min Res* 2003;18:1834-41.
- 128.) Donahue LR, Chang B, Mohan S, Miyakoshi N, Wegeal JE, Baylink DJ, Hawes NL, **Rosen CJ**, Ward-Bailey P, Zheng QY, Bronson RT, Johnson KR, and Davisson MT. A Missense mutation in the Mouse Col2A1 Gene Causes Spondyloepiphyseal Dysplasia Congenital, Hearing Loss and Retinoschisis. 2003 *J Bone Min Res* 18: 1612-1621.
- 129.) Sakata T, Halloran BP, Elalieh HZ, Munson SJ, Rudner L, Venton L, Ginzinger D, **Rosen CJ**, and Bikle DD. Skeletal unloading induces resistance to IGF-I on bone formation. 2003 *Bone* 32: 669-680.
- 130.) Ackert Bicknell C, Beamer WG, and **Rosen CJ**. N Acetyl Supplementation to Growing Mice. Changes in Growth Bone Size and Mass. 4<sup>th</sup> International Symposium on Nutrition and Bone Lausanne Switzerland, 2003 IN PRESS.
- 131.) Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garner P, Bouxsein ML, Bilezikian JP and **Rosen CJ**. The Effects of PTH and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. *NEJM* 2003: 349: 1207-15.
- 132.) **Rosen CJ**, Greenspan SL and Black DM. Vignettes in Osteoporosis: A Road Map to Successful Therapeutics

- 133.) Fan X, Roy E, Zhu L, Murphy T, Bicknell C, Hart M, Rosen CJ, Names MS and Rubin J. Nitric Oxide regulates RANKL and OPG expression in bone marrow stromal cells. *Endocrinology* 2004 :145:751-759
- 134.) Koller DL, Schriefer J, Sun Q, Shultz KL, Donahue LR, **Rosen CJ**, Forousd T, Beamer WG and Turner CH. Genetic effects for femoral biomechanics, structure and density in C57 BL/6J and C3H/HeJ Inbred Mouse Strains. *J Bone Min Res* 2003; 18: 1758-1766.
- 135.) Bouxsein ML, Uchiyama T, **Rosen CJ**, Shultz KS, Donahue LR, Turner CH, Sen S, Churchill GA, Muller R, and Beamer WG. Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. *J Bone Min Res* 2004:19:587-599
- 136.) Drake WM, Kendler DL, **Rosen CJ**, and Orwoll ES. An investigation of predictors of BMD and response to therapy with alendronate in osteoporotic men. *J Clin Endocrinol Metab* 2003; 88: 5759-5763.
- 137.) Turner CH, Sun Q, Schriefer J, Pitner N, Price R, Bouxsein ML, **Rosen CJ**, Donahue LR, Shultz KL, Beamer WG. Congenic mice reveal sex-specific genetic regulation of femoral structure and strength. *Calcif Tissue Int.* 2003 Sep; 73(3): 297-303.
- 138.) Stolzenberg-Solomon R, El-ghormli L, Schatzkin A, **Rosen C**, Clevidence B, Campbell W, Snyder K, Judd J, Taylor P 2004 Effects of a low fat, high fiber-carbohydrate diet on components of the IGF axis measured in plasma: a controlled feeding study in men. *Cancer Epidemiol Biomarkers Prev* 13(6):1086-7.
- 139.) Ackert-Bicknell CL, Beamer WG, and **Rosen CJ**. N-Acetyl Cysteine Supplementation of Growing Mice: Effects of Skeletal Size, Bone Mineral Density and Serum IGF-I. *Nutritional Aspects of Osteoporosis 2<sup>nd</sup> Edition* 2004: Elsevier Science; 351-360.
- 140.) **Rosen CJ** 2004 Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. *Best Practice & Research Clinical Endocrinology & Metabolism* 18(3):423-435.
- 141.) Miller, PD, Schnitzer, T, Emkey R, Orwoll, E, **Rosen, C**, Ettinger, M, Vandormael, K, Daifotis, A. Weekly oral alendronic acid in male osteoporosis. *Clinical Drug Investigation* 2004;24(6):333-341
- 142.) **Rosen, CJ** What's new with PTH in osteoporosis: Where are we and where are we headed? *TRENDS in Endocrinology and Metabolism*. Vol 15, No 5, July 2004
- 143.) Colbert LH, **Rosen CJ**, Goodpaster BH, et al. Insulin-like growth factor-1. *J Am Geriatr Soc* 2004; 52:1962-3.
- 144.) **Rosen CJ**, Ackert-Bicknell C, Beamer WG, Nelson T, Adamo N, Cohen P, Bouxsein ML and Horowitz MC. 2005 Allelic Differences in a QTL Affecting IGF-I Impact Skeletal Acquisition and Body Composition. *Pediatric Nephrology*; 20: 255-262
- 145.) Rosen CJ, Hochberg MC, Bonnicksen SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. *J Bone Miner Res* 20:141-51.
- 146.) Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A, Hollis BW, **Rosen CJ**, Wysolmerski JJ, Dann P, Gundberg C, Stewart AF 2005 Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)<sub>2</sub>Vitamin D. *J Bone Miner Res* 20:1792-1803
- 147.) Welch, J., **Rosen, C.J.**, 2005 Older women track and field athletes have enhanced calcaneal stiffness, *Osteoporosis International* 16:871-8

- 148.) Rubin MR, Schussheim DH, Kulak CA, Kurland ES, **Rosen CJ**, Bilezikian JP, Shane E 2005 Idiopathic osteoporosis in premenopausal women. *Osteoporos Int* 16:526-33.
- 149.) Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, **Rosen CJ** 8/11/2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med* 353:555-565.
- 150.) **Rosen CJ**. 2005 The Treatment and Prevention of Postmenopausal Osteoporosis. *N Engl J Med*: 353: 595-601.
- 151.) Bouxsein ML, Myers KS, Shultz KL, Donahue LR, **Rosen CJ**, Beamer WG 2005 Ovariectomy-induced bone loss varies among inbred strains of mice. *J Bone Miner Res* 20:1085-92
- 152.) Mohan S, Kapoor A, Singgih A, Zhang Z, Taylor T, Yu H, Chadwick RB, Chung YS, Donahue LR, **Rosen C**, Crawford GC, Wergedal J, Baylink DJ 2005 Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. *J Bone Miner Res* 20:1597-1610
- 153.) Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A, Hollis BW, **Rosen CJ**, Wysolmerski JJ, Dann P, Gundberg C, Stewart AF 2005 Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)<sub>2</sub>Vitamin D. *J Bone Miner Res* 20:1792-1803
- 154.) Jassal SK, von MD, Barrett-Connor E, **Rosen CJ**. 2005 Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: The Rancho Bernardo Study. *Osteoporos Int*; 16(12):1948-1954.
- 155.) Iida K, **Rosen CJ**, Ackert-Bicknell C, Thorner MO 2005 Genetic differences in the IGF-I gene among inbred strains of mice with different serum IGF-I levels. *J Endocrinol* 186:481-9
- 156.) Syed FA, Modder UI, Fraser DG, Spelsberg TC, **Rosen CJ**, Krust A, Chambon P, Jameson JL, Khosla S 2005 Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. *J Bone Miner Res* 20:1992-2001
- 157.) Sheu YT, Zmuda JM, Cauley JA, Moffett SP, Rosen CJ, Ishwad C, Ferrell RE 11/1/2005 Nuclear Receptor Coactivator-3 Alleles are Associated with Serum Bioavailable Testosterone, Insulin-Like Growth Factor-1, and Vertebral Bone Mass in Men. *J Clin Endocrinol Metab Rapid Electronic Publication* first published on Nov 1, 2005 as doi:doi:10.1210/jc.2005-0864
- 158.) Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, **Rosen CJ** 2005 Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. *Gastroenterology* 129(2):464-75.
- 159.) Sullivan S, **Rosen, CJ**, Halteman WA, Chen TC, and Holick MF 2005 Adolescent girls in Maine are at Risk for Vitamin D insufficiency. *J Am Dietetic Association* 105: 971-974.
- 160.) **Rosen, C.J.** 2005 The Role of Parathyroid Hormone in the Management of Osteoporosis. *Horm Res*; 64 (suppl 2): 81-85
- 161.) Yi-Hsiang H, Venners, SC, Terwedow HA, Feng Y, Niu T, Zhiping L, Laird N, Brain JD, Cummings SR, Bouxsein ML, **Rosen CJ**, Xu X 2005 Relationship of body composition, fat mass and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. *Am J Clin Nutrition* IN PRESS
- 162.) Akeson EC, Donahue LR, Beamer WG, Shultz KL, Ackert-Bicknell C, **Rosen CJ**, Corrigan J, Davisson MT 2005 Chromosomal inversion discovered in C3H/HeJ mice. *Genomics* IN PRESS
- 163.) Rosen CJ. 2005 Postmenopausal Osteoporosis. Letter response. *N Engl J Med* 353; 1974-75.

- 164.) Hsu YH, Niu T, Terwedow HA, Xu Xi, Feng Y, Li Z, Brain JD, **Rosen CJ**, Laird N and Xu X 2005 Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density in different skeletal sites in men. *Hum Genet* ; 118:568-577.
- 165.) Niu T, **Rosen CJ** 2005 The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. *Gene* 361:38-56
- 166.) Feng Y, Hsu YH, Terwedow H, Chen C, Xu X, Niu T, Zang T, Wu D, Tang G, Li Z, Hong X, Wang B, Brain JD, Cummings SR, **Rosen C**, Bouxsein ML, Xu X 2005 Familial aggregation of bone mineral density and bone mineral content in a Chinese population. *Osteoporos Int* 16:1917-1923
- 167.) Hsu Y, Delahunty KM, Niu T, Terwedow H, Lorenzo JA, Kream BE, Xu X, **Rosen CJ** 2005 Moving between mouse and humans to identify a candidate gene on Chr 10 that affects serum IGF-I, bone turnover and bone mineral density. *J Bone Miner Res* 20:S54
- 168.) Ishimori N, Li R, Walsh KA, Korstanje R, Rollins JA, Petkov P, Pletcher MT, Wiltshire T, Donahue LR, **Rosen CJ**, Beamer WG, Churchill GA, Paigen B 2006 Quantitative Trait Loci That Determine BMD in C57BL/6J and 129S1/SvImJ Inbred Mice. *J Bone Miner Res* 21:105-112
- 169.) He, J, **Rosen CJ**, Adams DJ and Kream BE 2006 Reduced Postnatal Growth and Bone Mass in Mice with IGF-I Haploinsufficiency. *Bone* IN PRESS
- 170.) Jiang J, Lichtler AC, Gronowicz GG, Adams, DJ, **Rosen CJ** and Kream BE 2006 Transgenic Mice with Osteoblast targeted IGF-I show increased growth and remodeling. *Bone* IN PRESS
- 171.) Munzer T, **Rosen CJ**, Harman SM, Pabst KM, St. Clair C, Sorkin JD, Blackman MR 2006 Effects of GH and Sex Steroids on Circulating Insulin-like Growth-Factor-Binding Proteins 1-5 (IGFBPs 1-5) in Healthy Aged Women and Men. *American Journal of Physiology, Endocrinology Metabolism* IN PRESS
- 172.) Yakar, S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair T, LeRoth D and **Rosen CJ** 2006 The Circulating Ternary IGF Complex Influences Postnatal Bone Acquisition and the Skeletal Response to Intermittent PTH. *J Endocrinol* IN PRESS
- 173.) Gordon, CM, **Rosen CJ**, et al 2006 Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. *Osteoporos Int.* IN PRESS
- 174.) Rubin J, Fan X, Rahnert J, Sen B, Hsieh C, Murphy TC, Nanes MS, Horton LG, Beamer WG and Rosen CJ. 2006 IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. *The Prostate* 999:1-12 IN PRESS
- 175.)

**APPEARS THIS WAY  
ON ORIGINAL**

**Review and Editorials in Peer Reviewed Journals (From 76 individual articles)**

1. **Rosen CJ**. Nutrition and Bone Health in the Elderly. *Clinical Reviews in Bone and Mineral Metabolism* 2004;1.
2. **Rosen CJ**. IGF-I and Calcium: Evolving aspects of an evolutionary process. *Endocrinology* 2003; 144:4679-4681

3. **Rosen CJ.** PTH analogues for the treatment of osteoporosis. Harrison's Textbook of Medicine ON LINE, 2003
4. **Rosen, CJ.** The Cellular and Clinical Parameters of Anabolic Therapy for Osteoporosis. *Critical Reviews in Eukaryotic Gene Expression*; 13(1):35-48(2003)
5. Brown SA and **Rosen CJ.** Osteoporosis. *Med Clin N America.* 2003; 87: 1039-1063.
6. Yakar S., **Rosen CJ** From mouse to main: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. *Exp Biol Med (Maywood)* Mar 2003; 228 (3):245-52.
7. **Rosen CJ.** Restoring aging bones. *Scientific American* Mar 2003;288(3):70-77.
8. **Rosen CJ** and Wuster CC. Growth Hormone Rising: Did We Quit Too Soon? *J Bone Min Res* 2003;18:406-409
9. Yakar S and **Rosen CJ.** The role of circulating IGF-I. *Endocrine*19: 239-248; 2002 .
10. Cranney A, Guyatt G, Wells G et al and the ORAG (**Cliff Rosen Chair**). Meta Analysis of Therapies for Postmenopausal Osteoporosis. *Endocrine Reviews* 2002; 4: 495-570
11. **Rosen CJ.** Add backs to prevent skeletal fragility: foresight or folly? *Menopause* May 2002 9(4):224-6
12. Chesnut CH, Lyles KW, **Rosen CJ.** Bone quality: enhancing the clinician's understanding of anti-resorptive therapies. *Clinical Geriatrics* 2001.
13. **Rosen CJ.** The Insulin like growth factor system and bone. *Curr Opin Endocrinol Diabetes* 2001 8:271-282.
14. Chesnut CH, **Rosen CJ.** Reconsidering the effects of anti-resorptive therapies in reducing osteoporotic fracture. *J Bone Min Res* 2001; 16: 2163-2173.
15. **Rosen CJ.** Biochemical markers of bone turnover as predictors of bone loss and response to therapy. In Bone Markers: Biochemical and Clinical Perspectives eds by Eastell R, Baumann M, Hoyle NR and Wiczorek L. Martin Dunitz, London England pp 187-197.
16. **Rosen CJ.** Conflict of interest: explicit rules. *J Clin Densitometry* 1999;3:209-210.
17. **Rosen CJ.** Treatment of postmenopausal osteoporosis: an evidence based approach. *Reviews in Endocrine and Metab Disorders* 2001;2: 35-43.
18. **Rosen CJ,** Donahue LR, and Beamer WG. Defining the genetics of osteoporosis: using the mouse to understand man. *Osteoporosis Int* 2001 12:803-810.
19. **Rosen CJ** and Bilezikian JP. Hot topics in Endocrinology: Anabolic Therapy in Osteoporosis. *J Clin Endocrinol Metab* 2001;86: 957-964.
20. **Rosen CJ.** Pathophysiology of Osteoporosis. *Clinics in Laboratory Medicine* 2000;20:455-468
21. **Rosen CJ.** IGF-I in Osteoporosis. *Clinics in Laboratory Medicine* 2000;20:591-602
22. **Rosen CJ** and Rackoff PJ. Emerging Anabolic Treatments for Osteoporosis. *Rheum Clinic North America* Ed by N Lane; 2001 27: 215-235
23. **Rosen CJ.** Pathogenesis of Osteoporosis *Clin Endocrinol Metab Balieri's*; 14: 2: 181-193. 2000
24. **Rosen CJ.** SERMS and Bone: *Menopause Management* 2000;9:23-26.



25. **Rosen CJ.** Fluoride and Fractures: An Ecologic Fallacy *Lancet* 2000;355:247-248.
26. **Rosen CJ** and Baran DT Thyroid Hormone and Bone Metabolism. Eds. by LE Braverman, Boots Flint Inc.Lincolnshire,Ill.1992 pp 13-17.
27. Beamer WG, Donahue LR and **Rosen CJ.** IGF-I and Bone: from mouse to man. International Symposium on GH and Growth Factors in Endocrinology and Metabolism; Growth Hormone and IGF research 2000;6; B S103-105
28. Crawford GC and **Rosen CJ.** Bone density in the management of Turner syndrome. Proceedings for the 5<sup>th</sup> International Turner Symposium-Optimizing Health Care for Turner Patients in the 21<sup>st</sup> Century Ed by P Saenger and Paquino. Elsevier- London Bl. 2000 p 263-265.
29. Bilezikian JP, Kurland ES, and **Rosen CJ.** Male Skeletal Health and Osteoporosis. *Trends in Endocrinol Metab* 1999;8:244-250.
30. **Rosen CJ** and Bilezikian JP. Perplexing polymorphisms: DIPS SNIPS and TRIPs. *J Clin Endocrinol Metab* 1999; 84:4465-66.
31. **Rosen CJ.** Serum IGF-I and IGF binding proteins: Clinical Implications. *Clin Chem* 1999; 45:1384-1390.
32. Rosen CJ. Growth hormone and Aging. *Endocrine* 2000;12;197-201.
33. Greenspan SL, Harris ST, Miller PD, Orwoll ES, Watts NB. and **Rosen CJ.** Bisphosphonates: Safety and Efficacy in the Treatment and Prevention of Postmenopausal Osteoporosis. *Am Family Physician* 2000;61:2731-2736.
34. **Rosen CJ.** Estrogens and SERMs: Mechanisms of Action and Role in the Prevention and Treatment of Osteoporosis. *Resident and Staff Physician* 2000;46 ; 10-16.
35. **Rosen CJ.** Health Care Reform in the United States: Implications for the management of patients with metabolic bone diseases. *J Bone Min Res* 1994;9;5: 595-598.
36. Coulston AM and **Rosen CJ.** Federal Health Care Reform: Implications for Medical Nutrition Therapy: *Am J Clin Nutrition* 1994;59:1275-76.
37. **Rosen CJ** The role of bisphosphonates and fluorides in the prevention and treatment of osteoporosis. *Top Ger Rehab* 1995;10;19-34.
38. **Rosen CJ.** Growth Hormone, Insulin-like Growth Factors and Senescent Bone: Revisiting Ponce de Leon's Fountain. *J Cell Biochem.*1994;58:1-9.
39. **Rosen CJ** and Donahue LR. Osteoporosis: Novel Treatment Strategies. *Drug News and Perspectives.* 1995 ;8:89-96.
40. **Rosen CJ** and Donahue LR. IGFs: Potential Therapeutic Options for Osteoporosis. *Trends Endocrinol Metab*;1995;6:235-241.
41. Kessenich CR and **Rosen CJ.** Comparative Pharmacology and Clinical Utilization of the Bisphosphonates. *Drugs.* 1996;51(4):537-551
- 42.Kessenich CR and **Rosen CJ.** Osteoporosis in Men. *Geriatric Nursing*;1996;17:171-174
- 43.Kessenich C and **Rosen CJ.** Vitamin D sufficiency in the elderly. *Orthoped Nursing*1996: 15:67-71.
- 44.Millard PS, **Rosen CJ** and Thomas S. Playing With a Stacked Deck: How the Maine Health Care Reform Commission Dealt Bad Cards to a Single Payer Plan. *Maine Public Policy Review* 1996;5:33-38.

45. **Rosen CJ** and Kessenich C. The role of IGF-I in Senescence: Implications for Therapy. *The Endocrinologist*. 1996;6:102-106.
46. Donahue LR and **Rosen CJ**. PTH and osteoporosis. *Current Opinions in Endocrinology* 1996, 3:6:532-540.
47. Millard PS, **Rosen CJ**, Johnson KH. Osteoporotic vertebral fractures in postmenopausal women. *Am Fam Phys* 1997;55:1315-1392
48. Kessenich CR and **Rosen CJ**. Risk Factors for Osteoporosis in Men; *Clin Geriatrics*; 1997.5:87-96.
49. **Rosen CJ** and Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis: an evidence based approach. *Clin Endocrinol Metab*;1997;26: 295-311.
50. **Rosen CJ** and Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. *Bone Depeche* 1997;3:1:15-18.
51. **Rosen CJ**. Endocrine diseases and osteoporosis. *Current Opinions in Rheumatology* 1997 1997;9:355-361.
52. **Rosen CJ**. Growth hormone, IGF-I and the elderly: Clues to potential therapeutic intervention. *Endocrine*; 1997 7:39-40.
53. Crawford-Sharpe, G and **Rosen CJ**. IGF-I and the Skeleton:New Perspectives. *The Endocrinologist*. 1999;9:81-86
54. **Rosen CJ**. Vitamin D; a review. *J Bone Min Res* 1998; 13:280
55. **Rosen CJ**. IGF-I and PTH: Future therapeutics for osteoporosis. *Expert Opinion on Investigational Drugs*. 1997 *Exp Opin Invest Drugs* 1997;6:1193-1198.
56. **Rosen CJ** and Pollak MF. IGF-I and Aging: A New Perspective for a New Century. *Trends in Endocrinol Metab* 1999;10: 136-142
57. **Rosen CJ**, Rackoff PJ, Pochenkova M and Barille D. Regulation of the IGF-I phenotype in Adults: potential heritable determinants. *DSL 4<sup>th</sup> International Meeting*; 1998;4:87-91.
58. **Rosen CJ** and Rackoff PJ. Clinical Utility of Ultrasound of the Calcaneus. *Diagnostic Imaging*; 1998; 20;S1; 11-15.
59. **Rosen CJ**, Holick MF and Chen TC. Seasonal Bone Loss in Elderly Women: Pathogenesis and Potential Implications. *Biologic Effects of Sunlight*. DeGruyter 1998.
60. Bilezikian JP, Kirland ES and **Rosen CJ**. Male skeletal health and osteoporosis. *Trends in Endocrinology and Metabolism*. 1999;8:244-250.
61. **Rosen CJ**. Pre-emptive bone strikes: Adding new targets for preventing osteoporosis *Lancet* 1998;351:927-928
62. **Rosen CJ** and Tenenhouse A. Biochemical Markers of Bone Turnover: Current and Future Clinical Perspectives. *Postgraduate Medicine* 1998; 104:101-114.
63. **Rosen CJ** and Bilezikian JP. Evolving towards a new paradigm for prevention of osteoporosis: the time is upon us. *J Clin Endocrinol Metab* 1997;82:2782-2783:
64. **Rosen CJ** and Conover C. The growth hormone IGF axis in aging; a summary of an NIA symposium. *J Clin Endocrinol Metab* 1997;82:3919-3923.
65. **Rosen CJ**. Endocrine Disorders and osteoporosis. *Current Opinion in Orthopedics*. 1997;8:38-44.
66. **Rosen CJ**. Prescribing etidronate for osteoporosis: a tale of two worlds. *Lancet* 1997;350:1340.

67. **Rosen CJ.** Biochemical markers of bone turnover in postmenopausal women. *Menopause Digest.* 1997;2:19.
68. Mussavi M and Rosen CJ. The Skeletal Response to HRT: Results of a Meta-analysis in *Menopause Management*; 1998;7:22-23.
69. **Rosen CJ.** The Serum IGF regulatory system: Mirror or Mirage. Proceedings of the 2nd and 3rd Annual DSL International Scientific Meetings. DSL. Houston Tx; 1997; pp208-210
70. Rackoff PJ and **Rosen CJ.** Epidemiology of glucocorticoid induced osteoporosis in the elderly. *Drugs and Aging*; 1998;6:477-484.
71. **Rosen CJ.** PTH: Where we are and where are we going. *Trends in Endocrinol Metab* 2004 Jul;15(5):229-33.
72. Colbert, L.H., **Rosen, C.J.**, Goodpaster, B.H., Newman, A.B., Kritchevsky, Satterfield, S, Kanaya, A.M., Taaffe, D.R., Harris, T.B., Letter to the Editor regarding insulin-like growth factor-I. *Journal of Aging Geriatrics*, 2004
73. **Rosen CJ** and Brown SA. A Rationale Approach to Evidence Gaps in the Management of Osteoporosis. *Am J Med* 2005; 118: 1183-1190.
74. **Rosen CJ** and Niu T. The IGF-I Gene and Osteoporosis: A Critical Re appraisal: *GENE* 2005; 361: 38-56.
75. **Rosen CJ.** Medical Letter: Treatment of Osteoporosis, 2005 IN PRESS;
76. **Rosen CJ.** PTH: Treatment for Osteoporosis. Up to Date, 2006 IN PRESS.

#### **BOOKS, BOOK CHAPTERS , and SPECIAL EDITIONS (From 26 books and chapters)**

1. **Rosen CJ** and Wuster C. Growth Hormone, Insulin-like growth factors: Potential applications and limitations in the management of osteoporosis. *Osteoporosis* eds by Feldman DW, Marcus R and Kelsey J. Academic Press, San Diego CA 1996:69:1313-1333.
2. *Osteoporosis: Diagnostic and Therapeutic Principles* ed by **Rosen CJ.** Humana Press 1996. Chapters 3, 11, 18. Towana, NJ.
3. **Rosen CJ.** Osteoporosis; in *Current Therapy.* eds by J. Snyder; 9th Edition 1996 pp 1168-1174.
4. **Rosen CJ** and Johannsson A. IGFs for the Treatment of Osteoporosis in *Principles of Bone Biology*, 1996 eds by J. Bilezikian, L. Raisz and G Rodan, Academic Press. San Diego CA pp1099-11.
5. **Rosen CJ.** *Vitamin D in Bone Health* in *Vitamin D: Basic Biology and Application* ed by MF Holick, Humana Press, 1998; pp 287-307
6. Compston JE and **Rosen CJ.** *Osteoporosis: Fast Facts. Editions I, II, III* Health Press, Oxford, England 1997-2002.
7. **Rosen CJ.** *IGF-I and its anabolic activity in bone.* in *Anabolic Treatments in Osteoporosis* ed by Whitfield F. CRC Press. 1997; Boca Raton Fla pp 185-205.
8. **Rosen CJ.** *Heart and Endocrine Diseases* in *Current Practice of Medicine*, ed 2; by Roger Bone and Faith Fitzgerald. Current Science Group, Phila PA; 36;1-8;1997
9. **Rosen CJ** and Conover C(eds). *Growth hormone and IGF-I in aging: A Symposium* *Endocrine* 1997;7: 39-125.
10. **Rosen CJ.** Age-related osteoporosis in *Cartilage and Bone Metabolism.* eds by Seibel M and Bilezikian JP. Academic Press, 1998 Books, Book Chapters and Special Editions pp 479-492
11. **Rosen CJ,** Bilezikian JP and Glowacki J. eds *The Aging Skeleton.* In Press 1999 Academic Press, San Diego CA
12. **Rosen CJ.** IGF-I in Men. in *Osteoporosis in Men*, ed by E Orwoll. Academic Press, 1999
13. Bilezikian JP, Kurland ES and **Rosen CJ.** Idiopathic osteoporosis in Men in *Osteoporosis in Men*; ed by E Orwoll. Academic Press, 1998
14. **Rosen CJ.** Bone Anabolic Agents; in *Atlas of Clinical Endocrinology.* Ed by Korenman S. 2000- Current Medicine Philadelphia Medicine, 169-179
15. Donahue LR and **Rosen CJ.** GH and IGF-I therapy in the elderly. In the *Aging Skeleton* ed by Rosen CJ, Bilezikian JP and Glowacki J. Academic Press 1999;.

16. **Rosen CJ.** Insulin like growth factors: clinical aspects. In Growth Factors and the Skeleton. Ed by Canalis E. Lippincott Press 2000. Pp 117-129
17. **Rosen CJ.** Guest Editor: Clinics in Laboratory Medicine: Osteoporosis In 2000
18. **Rosen CJ.** The Genetics of Osteoporosis. In the Osteoporotic Syndrome ed by Avioli LV; Academic 2000, San Diego CA; pp 37-45.
19. **Rosen CJ.** The Growth Hormone IGF-I Axis and Menopause in Menopause: Biology and Pathobiology ed by Lobo RE, Kelsey J and Marcus R. Academic Press 2000 San Diego CA, 271-282.
20. **Rosen CJ.** Pathogenesis of Osteoporosis in Endocrinologica. IN PRESS
21. **Rosen CJ.** Endocrine Disease and the Heart. In Cardiology for the Primary Care Physician ed I and II by J Alpert. 2001, 2004
22. Conover CA and **Rosen CJ.** IGFs and Bone. In Principles of Bone Biology 2002; ed by Bilezikian JP, Raisz L, and Rodan G. Academic Press 2002, San Diego CA. Pp 801-827.
23. **Rosen CJ.** Osteoporosis Pathophysiology and Epidemiology. In Endotext.com Textbook of Endocrinology; ed by DeGroot LJ. 2002, [www.Endotext.org](http://www.Endotext.org)
24. **Rosen CJ.** IGF-I and Bone Mineral Density: Experience from animal models and human observational studies. Best's Endocrinology 2004
25. **Rosen CJ.** Osteoporosis in Current Therapy 2005 IN PRESS.
26. **Rosen CJ and Brown S.** Osteoporosis and Bone in Evidence Based Endocrine Practice. In PRESS 2005 eds by Montori VM.
27. **Rosen CJ.** Osteoporosis in Cecil and Loeb Textbook of Medicine 2006. Chapter 258.

**APPEARS THIS WAY  
ON ORIGINAL**

## EDITORIAL POSITIONS

### I. **EDITORIAL BOARDS and POSITIONS:**

Journal of Bone and Mineral Research; 1992-2002  
Journal of Clinical Endocrinology and Metabolism; 1995-1999  
Menopause; 2000-2003  
Endocrinology 2004- 2008  
Osteoporosis: Index and Reviews; 1995-1998  
Calcified Tissue International; 1996-2003  
Bone; 2001 – present

EDITOR-IN CHIEF: *Journal of Clinical Densitometry*- 1997-2002  
**Associate Editor: Journal of Bone Mineral Research 2003-**  
**Editor in Chief- Primer on Metabolic Bone Diseases- 2006-**

### II. **AD HOC JOURNAL REVIEWER FOR PEER-REVIEWED JOURNALS:**

Growth Development and Aging	AM J Physiology
American Journal of Managed Care	American Journal of Medicine
American Journal of Physiology	American Journal of Obstetrics and Gynecology
Kidney International	Metabolism
Endocrinology	Journal of Cellular Biochemistry
Journal of Women's Health	American Journal of Clinical Nutrition
CRC Press	Growth Regulation
Peptides	Bone
Drugs	Hormone and Metabolic Research
Proceedings of the National Academy of Sciences	Journal of FASEB
Journal of the American Medical Association (JAMA)	Journal of Gerontology
Lancet	New England Journal of Medicine
AM Family Physician	Journal of Clinical Investigation
Primary Care Reports	Osteoporosis International
Plastic Reconstructive Surgery	

### III. **GOVERNMENT STUDY SECTION PEER REVIEW MEMBERSHIP:**

- 1) ad hoc; AIBS; American Institute of Biological Sciences NASA: Physiology and Countermeasures:1992-1997
- 2) ad hoc; NIH (NIDDK): Metabolic Bone Disease: 1992;1997
- 3) regular NIH: SSS#7; SBIR-1996-98
- 4) ad hoc; NOF(National Osteoporosis Foundation)-1993-1998
- 5) ad hoc:Veterans Affairs(VA):Merit Review; Endocrinology:1995-1997,1998
- 6) ad hoc: NIH(NIA)Aging and the Claude Pepper Centers for Excellence-1997
- 7) ad hoc: Swiss Science Foundation;1997
- 8) Chairperson: NIH-NICHD : RFA- Peak bone mass and osteoporosis;Dec 1997
- 9) ad hoc; NIH-Oral Biology and Medicine1997, 1998
- 10) ad hoc: NIH-NRSA; ZRG4 GRM(07)L
- 11) Chairperson: NIH-NICHD:Special Emphasis Panel-HD 37072;1998
- 12) Yale Bone and Metabolic Bone Disease Core-Scientific Reviewer
- 13) Chairperson-NIH OBM-2 SEP (ZRG-1)-November 16,1998
- 14) Reviewers Reserve: NASA- Countermeasures 1998-
- 15) Chairperson: Special Study Section NIH-NICHD-Behavioral Modifications and Peak Bone Mass, December 1998
- 16) Ad hoc NIA; Aging and the Claude Pepper Centers for Excellence-1999
- 17) Permanent Member Oral Biology and Medicine-2 NIH 1999-2002
- 18) Chair- Special Emphasis Panel NIH-NICHD- Bone Metabolism in Children-1999
- 19) Chair-Special Emphasis Panel NIH-NICHD-Bone Density in Children-2001
- 20) Permanent Chair- NIH Skeletal Biology Development and Disease(SBDD)- NIH peer review 2002-2004
- 21) Chair: Special Emphasis Panel NIAMS: LRP 5 and Bone 2003
- 22) Chair: DSMB: PTH in Glucocorticoid Induced Osteoporosis NIDDK

**SELECTED PEER-REVIEWED PUBLISHED ABSTRACTS (out of more than 300):**

1. Eastman RC, Bigos TL and Rosen CJ. Papillary Thyroid Cancer in an Endocrine Practice 67th Endocrine Society, #624 1985, Baltimore, MD.
2. Rosen CJ, Rosenthal B, and Andrews RC. "Bone Loss in Hyperthyroidism Measured by Dual Photon Absorptiometry", Maine Biologic Symposium, June 1986.
3. Rosen CJ, and Adler RA. Prolactin Levels Predict Bone Mineral Content in Hyperprolactinemia Women", 68th Endocrine Society #406 June 1987, Indianapolis, Indiana.
4. Rosen CJ, Owens MA and Adler RA. Altered Lymphocyte Subsets in Post Menopausal Osteoporosis", Am Soc Bone Min Res, Indianapolis, Indiana, September 1987.
5. Davee AM, Rosen CJ. Determinants of Vertebral Bone Density in Eumenorrheic College Women", American Dietetic Association, San Francisco, October 1988, 71st Annual Meeting.
6. Sherblom AS, Rosen CJ. "Uromodulin Mediated Clearance of IL-1 in Osteopenia", FASEB, #353I, New Orleans, March 1989.
7. Donahue LR, Russell SJ, Smith-Porter E, and Rosen CJ. Concentrations of Circulating IGF-I in the Elderly. 71st Meeting, The Endocrine Society, #380, Seattle, Washington.
8. Rosen CJ and Adler RA "Longitudinal Evaluation of Lumbar Spine Absorptiometry in Normal Post-Menopausal Women", AFCR, April 1989, #460A.
9. Donahue LR, and Rosen CJ. "Serum Low Molecular Weight Insulin-like Growth Factor Binding Protein in Type II Osteoporosis", ASBMR, #128 September 1989.
10. Donahue LR and Rosen CJ. "Age-Related Changes in Serum Insulin Like Growth-Factor Binding Proteins in Women" 72nd Annual Meeting Endocrine Society, Atlanta, Ga. June 20 1990.
11. Donahue LR and Rosen CJ. "Anorexia, Hypoglycemia, and the 30K Low Molecular Weight IGF-Binding Protein" 72nd Annual Meeting Endocrine Society, Atlanta, Ga. June 20, 1990
12. Donahue LR, Rosen CJ Spindler AA and Renvall M. "Increased IGF-I concentrations in institutionalized women with Alzheimer's disease. *Neurobiology of Aging* 11: 3,p256,1990.
13. Rosen CJ Acute Hemarthrosis as a Presentation of Primary Hyperparathyroidism. 1990 *J Bone Min Res* 5 Supp 2, #277.
14. Rosen CJ, Donahue LR, Ramsdell J, Spindler AA, Renvall M and Nichols J. Evidence for Alteration in the GH, IGF-I Axis of Alzheimer's Pts. International Somatomedin Mtg. CA. Jan 1991. #299
15. Simone K, Rosen CJ, Stene M. Relationship of endogenous and exogenous sex steroids to circulating IGF-I and IGFBP-3 in postmenopausal women. International Somatomedin Mtg. Jan 1991 #58
16. Mohan S, LaTour D, Linkhart T, Rosen CJ, Baylink DJ and Strong DD. Evidence that PTH increases the production of inhibitory IGFBP at the protein and mRNA levels in HBCs by a cyclic AMP dependent mechanism. International Somatomedin Mtg. Ca. Jan 1991 #58.
17. Rosen CJ, and Baylink DJ. Hypercalcemia associated with Adrenal Insufficiency. *J Bone Min Res* 6 Supp 1, Aug. 1991 (Boy Frame Abstract).
18. Hunter SJ, Peters LL, Higgins A, Wood BG, and Rosen CJ. Light Microscope Level Immunocytochemical Localization of Ankyrin and Spectrin in Chick Osteoclasts. *J Bone Min Res* 6 Supp 1, #271, 1991
19. P Linnel, Hermansen SJ, Elias M, Robbins M, Bing-You R, Kiel and Rosen CJ. Quality of Life in Osteoporotic Women *J Bone Min Res* 6 Supp 1 #96, 1991.
20. Rosen CJ, Donahue LR, Stene, M., Hodsman A, Fraher LJ, Mohan S and Baylink D. Pulsatile vs Sustained Hyperparathyroidism on the Serum IGF regulatory system. *J Bone Min Res* 6 Supp 1, 812, 1991.
21. Rosen C and Morrison T. Regulation of 1L-6 production by 1,25 vitamin D in skin fibroblasts. 17th Annual Maine Biologic Sciences Symposium.
22. Donahue LR, Rosen CJ and Beamer WG. Comparison of IGFbps in sera from normal and genetically small mice. 2nd Internat Somatomedin Mtg. #260. 1991.
23. Morrison T, Storm D, Chen T, Holick M Carlton E, and Rosen CJ. Exercise Induced Changes in IGF-1 and Osteocalcin in rural elderly women. 74th Endocrine Society Meeting, 1992 #1112.
24. Rosen CJ, Hunter S, Musgrave KO, Bing-you R. A three year study of lumbar BMD and calcium intake in early postmenopausal women without estrogen therapy. *J Bone Min Res* 1990; 5#2:140a.
25. Rosen CJ, Hunter SJ, Adler RA. Cyclic Etidronate and type II osteoporosis. *J Bone Min Res* 1991;6:#1 785a.
26. Rosen CJ, Hunter SJ, Zhao, HP, Storm DS, Holick M, Chen T. Seasonal changes in bone mass and biochemical markers in elderly rural women *J Bone Min Research* 1992;8;S#1 324.
27. Rosen CJ, Morrison AM, Fraher LJ, Hodsman A. In vivo regulation of the GH-IGF-I Axis by PTH. *Calcified Tissue Int*; 1993;52:S#2
28. Morrison T, Storm D, Zhou H, Rosen C. IGFBP profiles predict bone turnover and exercise induced GH changes in elderly women. 75th Endocrine Society 1993:#687

29. Stock JL, Rosen CJ, Shewmon DA, Morrison T, Heiniluoma KM, Coderre JA. Effects of Estrogen and Tamoxifen on IGF-I and IGFBP-3 in healthy postmenopausal women. 75th Endocrine Society;1993:1327
30. Shewmon D, Stock JL, Rosen CJ et al. Serum IGF-I correlates with changes in Lp(a) during treatment with estrogen and tamoxifen. *Circulation* 1993 S#1.
31. Shewmon D, Roy V, Heiniluoma K, Hogue M, Rosen C and Morrison T. Niacin therapy decreases serum concentration of IGF-I in parallel with those of lipoprotein (a). GHRH, GH and IGF-I: Basic and Clinical Advances. Serono Symposium; December 13, 1993; San Diego CA.
32. Plymate SR, Rosen CJ, Paulsen CA and Birnbaum RA. Insulin-like growth factor binding protein measurements in seminal fluid. AFCR-Western Meeting: *Clin Res* 42:20A;1994.
33. Rosen CJ, Holick MF. Premature Graying of Hair May be a Risk Factor for Osteopenia. Endocrine Society 77th Session 1994, Anaheim CA.
34. Rosen CJ, Bilezikian J and Hodsman AM. Effects of Parathyroid Hormone on IGF-I and IGFBPs. Endocrine Society 77th Session Anaheim CA 1994.
35. Donahue LR, Rosen CJ and Beamer WG. Reduced bone density in hypogonadal mice. *J Bone Min Res* 1994;9S1 A 244.
36. Dalsky GP, Rosen CJ, Fenster JR, Biskup BG, Vereault D. Serum IGF-I and body composition in older men and women. *J Bone Min Res* 1994;9:S1;A342.
37. Zhou H, Putzi M, Rosen CJ, Hunter SJ. Development of Chick Osteoclasts from Embryonic Bone Marrow. *J Bone Min Res* 1994;9 S1.
38. Rosen CJ, Kiel DP, MacLean DB. Serum IGF-I and its relationship to bone mass in frail elders. *J Bone Min Res* 1994;9:S1 C242.
39. Kessenich CR and Rosen CJ. Vitamin D Sufficiency in elderly osteoporotic women: Time Dose and Geographic Effects. Endocrine Society, 1995 P2-622.
40. Rosen CJ, Steffens, C, LeBoff M and Glowacki J. Effects of age on the skeletal IGF regulatory system. Endocrine Society 1995 P3-676.
41. Rosen CJ, Vereault DV, Steffens C, Chen TC, Hunter SJ, Holick MF, Mohan S, Baylink DJ. Mechanisms Responsible for Seasonal Bone loss in Elderly Women. *J Bone Min Res* 1995; 10;S 476.
42. MacLean DB, Kiel DP, and Rosen CJ. Low dose GH for frail elders stimulates bone turnover in a dose-dependent manner. *J Bone Min Res* 1995;10:S458.
43. Rosen CJ, MacLean DB and Kiel DP. GH stimulates bone turnover and bone loss in a dose-dependent manner. Endocrine Society 1996 78th Annual Meeting

**INVITED LECTURES OF MAJOR SIGNIFICANCE:**

1. Dartmouth Hitchcock Medical Center, June 4, 1986, "Prolactinomas"; March 27, 1989-New Aspects of Osteoporosis.
2. American College of Physicians Regional Meeting, Hanover, NH, October 31, 1984, "Prolactinoma - A Five Year Experience".
3. Berkshire Medical Center, Pittsfield Massachusetts, May 16, 1986, "Pathophysiology of Type II NIDDM"; May 4, 1989, "Clinical Significance of Insulin-like Growth Factors".
4. Eastern Maine Medical Center, April 1986 - "Newer Concepts in Osteoporosis"; January 1985 - "Hyperthyroidism - Unusual Aspects".
5. Maine Medical Center, November 13, 1987 - "Immunologic Aspects of Bone Turnover", Endocrine Rounds, Grand Rounds, August 9, 1989. "New Aspects of Osteoporosis".
6. Berkshire Medical Center, "Osteoporosis", September 27, 1988, "Growth Factors", May 23, 1989.
7. Boston University Medical Center, Endocrine Grand Rounds, "Immunologic Aspects of Osteopenia", October 13, 1988.
8. University of California, San Diego, January 24, 1990, Medical Grand Rounds, "Growth Factors: Applications and Implications"
9. Loma Linda University-Dept. of Bone and Mineral Research: Mechanistic Approaches to Type II Osteoporosis, Jan 25, 1990.
10. Boston University School of Medicine: Faculty for the Course: An Review of Osteoporosis. Boston, Mass. May 18, 1990. Controversies in Internal Medicine: May 5-11, 1990 Hilton Head, So. Carolina
11. Walter Reed Army Hospital November 1990: Clinical Aspects of the Insulin-Like Growth Factors. Endocrine Grand Rounds
12. Loma Linda University and JL Pettis VA Hospital: Bone and Mineral Division: Update on the 24 kD IGFBP; May 13, 1991.
13. Boston University School of Medicine: Grand Rounds-Update on Estrogen and Osteoporosis; November 12, 1991.
14. University of Massachusetts Medical Center-Endocrine Grand Rounds: Significance of the 24 kD IGF Binding Protein; March 10, 1992
15. Nichols Institute, San Juan Capistrano, CA; Jan 15, 1992: The clinical significance of the IGF binding protein.
16. Seasonal Effects of Sunlight on Bone Mass in Elders. The 2nd international symposium on the biologic effects of light. Basel Switzerland, June 3, 1993.
17. Clinical Ligand Assay Society: Clinical Significance of the IGFs and their binding proteins. Boston November 18, 1993.
18. Columbia University School of Medicine, Endocrine Grand Rounds, November 12, 1993: The IGFs and their significance.
19. Institute for Molecular Biology November 9, 1993. Clinical Significance of the IGF regulatory system.

20. Beth Israel Hospital Seminar, Boston MA:PTH and the IGF regulatory system. November 14,1993.

#### **VISITING PROFESSOR AND LECTURER:**

1. Boston University-Dept. of Endocrinology. "Applications of the IGF Binding Proteins to Clinical Medicine". Nov. 1989
2. University of California San Diego-Dept.of General Internal Medicine and San Diego State University- Jan.23- 30,1990. Visiting Professor Sponsored by Institute of Aging Research
3. San Diego State University - January 1990, Dept. of Nutrition.
4. Kennebec Valley Medical Center - April 1985, "Type II NIDDM".
5. Mt. Desert Island and Jackson Laboratory - August 1985, "Symposium on the Cellular Mechanisms of Insulin Action".
6. Dartmouth Hitchcock Medical Center - May 1986, Endocrine Grand Rounds, "Hyperthyroid Bone Loss".
7. University of Zimbabwe - June 1986, visiting lecturer for one week, "Prolactinoma".
8. University of Maine, Dept. of Biochemistry - January 1987, "Post Receptor Events in the Pathophysiology of Type II NIDDM", January 1989, "Immunologic Aspects of Osteoporosis".
9. Mid-Maine Medical Center Waterville Maine- May 1986, "Aspects of Hyperthyroidism".
10. American College of Physicians, regional meeting - Fall 1987, "Hirsutism", Bar Harbor, Maine.
11. Dixon Symposium on Back Pain, Bethel Inn - March 1988, "Osteoporosis".
12. Cornell University, Dept. of Nutrition - March 1989, "IGF and Nutrition".
13. Coordinator of the 2nd and 3rd Annual Mason Trowbridge Clinical Research Day: Eastern Maine Medical Center June 23, 1989; Oct, 1991
14. McMasters University Medical Center : Visiting Professor-Grand Rounds "Clinician's view of IGF-I and its binding proteins" and presentation at academic half-day visiting professor rounds: Osteoporosis. February 11-14, 1991.
15. Lawson Research Institute, University of Western Ontario "IGF-I/IGF Binding Proteins and Bone Remodeling" March 27, 1991
16. Southern California Bone and Mineral Club: SanBernadino, California "Exercise and Growth Factors", May 1991
17. Clinical Decision Making in Geriatrics: Bar Harbor, ME June 1991; Topic: Osteoporosis.
18. Boston City Hospital: "Estrogen Use in Menopause". The Friday Conference. September 8, 1991.
19. Dartmouth Hitchcock Medical Center Grand Rounds: New aspects in the diagnosis and treatment of osteoporosis. February 28, 1992.
20. 74th Annual Endocrine Society: Satellite Program: Thyroid hormone and Bone metabolism. June 24, 1992.
21. Pharmaceutical and Educational Research Institute: Osteoporosis, May 6, 1992.
22. Course Co-Director:PERI New Modalities in the diagnosis and treatment of Osteoporosis. Boston MA May 4-6, 1993-1995.
23. Mary Imogene Bassett Hospital:Cooperstown NY:Research Grand Rounds: Clinical implications of the IGFs. May 27, 1993
24. Mary Fletcher Hospital-University of Vermont Medical Center: Medical Grand Rounds August 3, 1993; New Medicine for Old Bones
25. University of Vermont: Metabolic Grand Rounds: August 3, 1993 Effects of Thyroid Hormone on Bone.
26. Course Co-Director: Pharmaceutical Education and Research Institute, 1994: Osteoporosis: Basic and Clinical Aspects.
27. J L Pettis Veterans Administration Hospital: Bone and Mineral Rounds: December 8, 1993 - PTH and IGF-I:Fact or Fancy.
28. University of Arkansas Medical School: Medicine Grand Rounds: Treatment of Osteoporosis: March 17, 1994
29. Upstate Medical Center Health Science Center:PTH-IGF-I Fact or Fancy: Special Endocrine Seminar April 4, 1994.
30. American Academy of Physician Assistants National Congress. San Antonio, Texas May, 1994; Keynote address: Osteoporosis: Update.
31. The Jackson Laboratory: Seminar: New Drugs for Old Bones. June 23, 1994.
32. Insulin-like growth factors in the treatment of osteoporosis. Alza Technologies, Palo Alto California; August 15, 1994.
33. University of Adelaide: IGFs and Bone: Mirror or Mirage-November 15, 1994
34. Medical College of Virginia: Grand Rounds: December 2, 1994 New Drugs for Old Bones
35. Geriatric Society of American:Discussant Is IGF-I a Surrogate Measure of GH secretion: The Gerontologist, 365 1994.
36. Endocrine Grand Rounds: Brigham and Women's Hospital: January 27, 1994 The IGF regulatory system and PTH.
37. Pediatric Grand Rounds: University of Cincinnati Medical Center: February 2, 1995. The IGFs and Bone.
38. Bedford Veterans Hospital; Bedford MA: Grand Rounds: New Treatment strategies for bone disease. Jan 25, 1995.
39. Grand Rounds: Eastern Maine Medical Center: An update on the therapy for osteoporosis; February 25, 1995
40. Advances in Mineral Metabolism: April 2, 1995: Snowmass: The IGFs and Bone
41. Visiting Professor: Academic Half Day: McMaster University Medical Center-Hamilton ONT; May 23, 1995
42. Harvard Medical School Seminars on Aging: May 22, 1995: IGFs and Bone.
43. Colorado Bone and Mineral Society: Sept 22, 1995:Cytokines, IGFs and Bone
44. University of Wisconsin: Endocrinology and Nutrition Grand Rounds; Oct 11, 1995;
45. Yale University: Orthopedics Department: November 30, 1995



46. Mayo Clinic and Medical School: Visiting professor: Dec 1-7,1995
47. Boston University Grand Rounds-Dept. of Medicine April 11,1996: Glucocorticoid-induced osteoporosis.
48. University of Texas-Galveston-Visiting professor in orthopedic research May 4-6,1996
49. Southwest Foundation for Medical Research-San Antonio, May 6-8,1996;
50. American College of Rheumatology- Oct 21,1996: Recent advances in Osteoporosis
51. Cambridge Health Institute:Visiting Speaker-Use of N-telopeptide: Oct 16,1996
52. University of North Carolina: Update in Osteoporosis; Dec 2,1996
53. Visiting Professor-Case Western Reserve University Hospitals: Dec 11-13,1996
54. Grand Rounds-Endocrinology-University of Mass Med Center-March 11,1997
55. Visiting Professor: University of Arizona-April 30-May 2,1997
56. Bayer Visiting Professor-Yale University Medical Center-Oct 15,1997
57. Plenary Lecture Australia New Zealand Bone Mineral Society-Sept 30,1997
58. Lunch: Meet the Professor- North American Menopause Society-Sept 4,1997
59. Am Society of Clin Chemistry-July 23,1997: IGFs and aging
60. Berkshire Medical Center-Pittsfield MA Oct 31,1997
61. Am Society of Bone Min Research: IGFs and Aging- September 11,1997;
62. University of Heidelberg: IGFs and Bone-April 28,1998
63. Endocrine Society: Osteoporosis Symposium New Orleans 1998: Anabolic Factors for Bone
64. Grand Rounds – Columbia Presbyterian Hospital- New York NY; Nov 22,1998
65. Chairperson-Clinical Issues in Ultrasound-ASBMR- San Francisco- CA
66. Grand Rounds-Boston University School of Medicine-Oct 24,1998
67. American College of Rheumatology(ACR)-Annual Meeting Anabolic Factors Nov 1998;
68. Endocrine Society 2002: IGFs and Bone
69. Gordon Conference IGFs and Bone 2003 Ventura CA
70. NIH Great Clinical Teachers Lecture Series Dec 2002
71. GH and IGFs Annual Meeting; IGFs and Aging: October 2002
72. Grand Rounds University of Manitoba October 2002: Evidence Based Approaches to Osteoporosis
73. Gordon Research Conference on IGFs Ventura California March 2003: Circulating IGF-I and Bone
74. Grand Rounds Children's Hospital of Los Angeles November 2003: IGF and Bone
75. Grand Rounds in Geriatrics University of Colorado Health Sciences Center- October 2003
76. FASEB Plenary Symposium: Sex Genes and Bone: April 2003 San Diego CA
77. Children's Hospital, Harvard University Grand Rounds: October 2005
78. Endocrine Society Plenary Symposium: Genetics of Osteoporosis, San Diego CA June 2005.

**APPEARS THIS WAY  
ON ORIGINAL**